Ribonexus SAS

Ribonexus (previously Aglaia Therapeutics) is a biotechnology startup developing promising new oncology therapies. The company aims at delivering best- and first- in class drugs that restore sensitivity to current targeted therapies in cancer patients that have become resistant to these treatments. Ribonexus has established a pipeline of small molecules, targeting the initiation of mRNA translation, which the company acquired and developed through Pierre Fabre. Based in Villejuif, near Paris, France, Ribonexus was co-founded in 2021 by Advent France Biotechnology (AFB). The company raised €4M ($4.7M) in seed funding from AFB, Credit Mutuel Innovation and Pierre Fabre to start its preclinical activities. *

	Start	2021-11-01 renamed
	Predecessor	Aglaia Therapeutics SAS
	Industry	RNA-targeting small molecule drugs (rSMs)
	Industry 2	cancer drug
	Person	Chorny, Alejo (Advent France Biotechnology 202109 Operating Partner + COO at Aglaia Therapeutics)

	Region	Villejuif
	Country	France
	Street	39 Rue Camille Desmoulins
	City	94800 Villejuif
		Address record changed: 2021-11-21

Basic data	Employees	n. a.

		* Document for »About Section«: Ribonexus. (11/18/21). "Press Release: Aglaia Therapeutics Becomes Ribonexus and Signs Exclusive License Agreement with Pierre Fabre on Small Molecules Targeting eIF4A, an Innovative Target in Oncology". Villejuif & Castres.

		Record changed: 2024-03-30